TUMOR, SOLID

This study tested the Varian ProBeam proton therapy system in 47 people with solid tumors. The goal was to see if the device safely controls tumors and meets performance standards. Patients received proton radiation and were followed for up to 5 years after treatment.

This study tested a new proton therapy device, the Varian ProBeam360°, in 47 people with solid tumors. The goal was to see if it could control tumor growth with few severe side effects. Participants received radiation for 1 to 8 weeks and were followed for up to 5 years. The main…

This study tested a new device that uses focused ultrasound (histotripsy) to break apart solid kidney tumors without making any cuts. Twenty adults with small, non-spreading kidney tumors were treated. The main goals were to see if the device could fully cover the tumor and if th…

This early-phase trial tested a new immunotherapy drug called BDB001, alone or combined with atezolizumab (Tecentriq), in 40 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if t…

This phase 2 study tested a combination of two immunotherapy drugs, durvalumab and tremelimumab, in 14 adults with recurrent solid tumors that had a high number of genetic mutations. The goal was to see if the treatment could slow cancer growth compared to their prior therapy. Th…

This early-phase trial tested a new immunotherapy drug called BDB001, both alone and combined with pembrolizumab, in 87 adults with advanced solid tumors that had progressed after standard treatments. The main goals were to check safety and find the best dose. The study is comple…

This study tested an experimental drug called BDB001 in people with advanced solid tumors (like skin, lung, or kidney cancer) that had stopped responding to standard immunotherapy. The goal was to see if BDB001 could shrink tumors or slow their growth. Only one person took part, …

This early-phase study tested a new immunotherapy drug called BDB018, given alone or with pembrolizumab, in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Only one person took part, …

This early-phase study tested a new antibody called HMBD-002, given alone or with pembrolizumab, in 48 adults with advanced solid tumors (like lung or breast cancer) that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and s…